Oct 29, 4:07 PM ET
Illumina announced third-quarter 2026 financial results with reported revenue of $1.13 billion, representing a 4.2% increase compared to the prior-year period. Driven by healthy clinical demand and NovaSeq X placements, the company raised its full-year 2026 total revenue guidance to $4.64-$4.66 billion and non-GAAP diluted EPS guidance to $5.40-$5.45.
- Reported revenue for Q3 2026 was $1.13 billion, up 4.2% from Q3 2025.
- GAAP diluted EPS for Q3 2026 was $1.43, compared to $0.98 in Q3 2025.
- Free cash flow for Q3 2026 reached $378 million, compared to $253 million in the prior-year period.
- Full-year 2026 revenue guidance was raised to $4.64-$4.66 billion, up from the previous range.
Read the filing on SEC.gov ↗
Oct 13, 4:48 PM ET
Illumina entered into dealer agreements on October 8, 2026, to establish an unsecured commercial paper program allowing short-term notes of up to $1.0 billion outstanding at any time. The company said no notes were outstanding as of the filing date and proceeds are expected to fund general corporate purposes, so the program adds borrowing capacity rather than existing debt.
- Program caps outstanding CP Notes at $1.0 billion; no notes were outstanding as of the filing date
- Maturities may not exceed 397 days from the date of issue
- Three commercial paper dealers and a national bank as issuing and paying agent
- Proceeds expected for general corporate purposes; dealer agreement form filed as Exhibit 10.1
Read the filing on SEC.gov ↗
Aug 13, 4:18 PM ET
On August 13, 2026, Illumina entered into a new $1,000 million senior unsecured five-year revolving credit facility with Bank of America, N.A. as administrative agent, which replaces the Existing Credit Agreement dated January 4, 2023, that was terminated the same day. As of the filing date, no borrowings were outstanding, and the facility matures on August 13, 2031, subject to extension options.
- Facility size: $1,000 million senior unsecured five-year revolving credit, with a $50 million swingline sublimit and a $75 million letter of credit sublimit
- Option to add up to $500 million in term loans or commitment increases, subject to lender consent
- No borrowings outstanding as of the filing date; maturity August 13, 2031
- Existing Credit Agreement dated January 4, 2023 was terminated as of August 13, 2026
Read the filing on SEC.gov ↗
Jul 30, 4:07 PM ET
Illumina reported second-quarter 2026 revenue of $1.16 billion, up 9.5% from a year earlier, and non-GAAP diluted EPS of $1.31, up from $1.19. GAAP diluted EPS fell to $1.35 from $1.49, and the company raised its fiscal 2026 revenue and non-GAAP EPS guidance. For shareholders, the higher outlook is the key development, though GAAP earnings declined year over year.
- Q2 2026 revenue was $1.16 billion, up 9.5% from Q2 2025; non-GAAP diluted EPS was $1.31 versus $1.19, while GAAP diluted EPS was $1.35 versus $1.49
- Fiscal 2026 total revenue guidance raised to $4.60-$4.64 billion from $4.52-$4.62 billion
- Fiscal 2026 non-GAAP diluted EPS guidance raised to $5.30-$5.40 from $5.15-$5.30; non-GAAP operating margin guidance unchanged at 23.4%-23.6%
- Free cash flow was $162 million for Q2 2026, compared with $204 million a year earlier
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.